Meta-Analysis
Copyright ©The Author(s) 2022.
World J Meta-Anal. Apr 28, 2022; 10(2): 63-73
Published online Apr 28, 2022. doi: 10.13105/wjma.v10.i2.63
Table 1 Characteristics of eligible studies
Ref.
Study design
Treatment
No. of patients
Gender (M/F)
Age
Intervention time
Primary outcome
Test
Control
Test
Control
Test
Control
Test
Control
Ji et al[23]RCTAuricular plaster + NifedipineNifedipine323217/1516/1666.06 ± 4.3966.16 ± 4.223 mo2, 3
Zhou et al[32]RCTAuricular plaster + Candesartan CilexetilCandesartan Cilexetil404024/1621/1965.78 ± 9.9566.12 ± 8.572 wk1, 2, 3
Huang et al[28]RCTAuricular plaster + Levamlodipine besylateLevamlodipine besylate303017/1319/1160-8560-8515 d1, 2, 3
Wu et al[29]RCTAuricular plaster + Conventional drugsConventional drugs414123/1821/2060-7060-706 wk1, 2, 3
Zhou et al[31]RCTAuricular plaster + NifedipineNifedipine303016/1414/1663.21 ± 12.2563.55 ± 11.744 wk1, 2, 3
Lin et al[26]RCTAuricular plaster + Levamlodipine besylateLevamlodipine besylate303016/1414/1666.73 ± 6.8167.6 ± 7.514 wk1, 4
Zhou et al[33]RCTAuricular plaster + Conventional drugsConventional drugs303021/919/1162-8362-833 mo1, 2, 3, 4
Zhang et al[21]RCTAuricular plaster + Amlodipine besylateAmlodipine besylate20209/1112/863.4 ± 5.264.8 ± 4.72 wk1, 2, 3
Jiang et al[34]RCTAuricular plaster + NifedipineNifedipine545430/2431/2365.8 ± 7.364.1 ± 7.24 wk1, 2, 3, 4
Yu et al[25]RCTAuricular plaster + NifedipineNifedipine877939/4837/4268.1 ± 10.771.1 ± 8.05 mo1, 2, 3
Zhang et al[24]RCTAuricular plaster + PropranololPropranolol434325/1827/1663.02 ± 8.3362.13 ± 7.9615 d2, 3
Lu et al[27]RCTAuricular plaster + Conventional drugsConventional drugs505026/2427/2360.26 ± 6.7361.35 ± 6.563 wk1, 2, 3
Zou et al[30]RCTAuricular plaster + Levamlodipine besylateLevamlodipine besylate202012/814/662.6 ± 10.362.9 ± 10.54 wk1, 2, 3
Yu et al[22]RCTAuricular plaster + Amlodipine besylateAmlodipine besylate414124/1726/1566.4 ± 3.467.1 ± 3.78 wk1, 2, 3, 4